| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.01 | 0.9 |